ReviewDrugs & aging1997
Matrix metalloproteinases. Novel targets for directed cancer therapy.
Review in Drugs & aging, 1997. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 137 citations in OpenAlex.
- The most likely but largely ignored triggering factor for breast (or all) cancer invasion.Journal of Cancer · 2023Article
- Etiology of Inguinal Hernias: A Comprehensive Review.Frontiers in surgery · 2017Review
- Advances in fluorescent-image guided surgery.Annals of translational medicine · 2016Review
- EGR1 controls divergent cellular responses of distinctive nucleus pulposus cell types.BMC musculoskeletal disorders · 2016Article
- Terminalia catappa attenuates urokinase-type plasminogen activator expression through Erk pathways in Hepatocellular carcinoma.BMC complementary and alternative medicine · 2014Article
- Extracellular matrix remodeling: the common denominator in connective tissue diseases. Possibilities for evaluation and current understanding of the matrix as more than a passive architecture, but a key player in tissue failure.Assay and drug development technologies · 2013Review
- New insights into the mechanisms of green tea catechins in the chemoprevention of prostate cancer.Nutrition and cancer · 2012Review
- Recombinant GPI-anchored TIMP-1 stimulates growth and migration of peritoneal mesothelial cells.PloS one · 2012Article
- NAHA, a novel hydroxamic acid-derivative, inhibits growth and angiogenesis of breast cancer in vitro and in vivo.PloS one · 2012Article
- Increased methylation variation in epigenetic domains across cancer types.Nature genetics · 2011Article
- Interleukin-12 deficiency is permissive for angiogenesis in UV radiation-induced skin tumors.Cancer research · 2007Article
- The effects of curcumin on the invasiveness of prostate cancer in vitro and in vivo.Prostate cancer and prostatic diseases · 2006Article
- The p75(NTR) metastasis suppressor inhibits urokinase plasminogen activator, matrix metalloproteinase-2 and matrix metalloproteinase-9 in PC-3 prostate cancer cells.Clinical & experimental metastasis · 2006Article
- Molecular optical imaging: applications leading to the development of present day therapeutics.NeuroRx : the journal of the American Society for Experimental NeuroTherapeutics · 2005Review
- Simultaneous determination of matrix metalloproteinase (MMP)-7, MMP-1, -3, and -13 gene expression by multiplex PCR in colorectal carcinomas.International journal of colorectal disease · 2004Article
- In vitro and in vivo endochondral bone formation models allow identification of anti-angiogenic compounds.The American journal of pathology · 2003Article
- Growth factor-dependent activation of the MAPK pathway in human pancreatic cancer: MEK/ERK and p38 MAP kinase interaction in uPA synthesis.Clinical & experimental metastasis · 2003Article
- Activity of biphenyl matrix metalloproteinase inhibitor BAY 12-9566 in a human breast cancer orthotopic model.Clinical & experimental metastasis · 2003Article
- Identification of human renal cell carcinoma associated genes by suppression subtractive hybridization.British journal of cancer · 2001Article
- A case of tumor betrayal: biphasic effects of TIMP-1 on Burkitt's lymphoma.The American journal of pathology · 2001Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Matrix metalloproteinases (MMPs), or matrixins, are a family of zinc endopeptidases that play a key role in both physiological and pathological tissue degradation. Normally, there is a careful balance between cell division, matrix synthesis and matrix degradation, which is under the control of cytokines, growth factors and cell matrix interactions. The MMPs are involved in remodelling during tissue morphogenesis and wound healing. Under pathological conditions, this balance is altered: in arthritis, there is uncontrolled destruction of cartilage; in cancer, increased matrix turnover is thought to promote tumour cell invasion. The demonstration of a functional role of MMPs in arthritis and tumour metastasis raises the possibility of therapeutic intervention using synthetic MMP inhibitors with appropriate selectivity and pharmacokinetics. As the process of drug discovery focuses on structure-based design, efforts to resolve the 3-dimensional structures of the MMP family have intensified. Several novel MMP inhibitors have been identified and are currently being investigated in clinical trials. The structural information that is rapidly accumulating will be useful in refining the available inhibitors to selectively target specific MMP family members. In this review, we focus on the role of MMPs and their inhibitors in tumour invasion, metastasis and angiogenesis, and examine how MMPs may be targeted to prevent cancer progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.